Skip to Content

Theratechnologies Inc THTX

Morningstar Rating
$1.30 +0.04 (3.17%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

THTX is trading at a 865% premium.
Price
$1.30
Fair Value
$7.68
Uncertainty
Very High
1-Star Price
$8.68
5-Star Price
$4.53
Economic Moat
Bvpl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if THTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.26
Day Range
$1.271.30
52-Week Range
$0.883.92
Bid/Ask
$1.21 / $1.30
Market Cap
$59.77 Mil
Volume/Avg
6,143 / 20,930

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.54
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
103

Comparables

Valuation

Metric
THTX
VSBC
TLX
Price/Earnings (Normalized)
3,629.76130.78
Price/Book Value
1,908.6236.11
Price/Sales
0.54664.5310.67
Price/Cash Flow
2,904.34221.97
Price/Earnings
THTX
VSBC
TLX

Financial Strength

Metric
THTX
VSBC
TLX
Quick Ratio
0.974.321.19
Current Ratio
1.154.331.43
Interest Coverage
−0.731.15
Quick Ratio
THTX
VSBC
TLX

Profitability

Metric
THTX
VSBC
TLX
Return on Assets (Normalized)
−24.06%42.38%3.71%
Return on Equity (Normalized)
65.38%11.73%
Return on Invested Capital (Normalized)
−37.92%55.23%18.08%
Return on Assets
THTX
VSBC
TLX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
PyrhdtmcMhnvd$124.1 Bil
Regeneron Pharmaceuticals Inc
REGN
KhkltkxsYctvbl$114.2 Bil
Moderna Inc
MRNA
VphdzzgzMlkh$53.7 Bil
argenx SE ADR
ARGX
NpltgbkcVrhy$23.0 Bil
BioNTech SE ADR
BNTX
LbgrcqyxQwqh$22.2 Bil
Alnylam Pharmaceuticals Inc
ALNY
JsdwlbfwhGskkcv$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
NkjvdgpcPpsspm$15.9 Bil
United Therapeutics Corp
UTHR
MqcqznsjZqly$12.8 Bil
Incyte Corp
INCY
RnzjqwcnfVkqpwv$12.2 Bil
Royalty Pharma PLC Class A
RPRX
BmdvrptcfqJzzchv$12.2 Bil

Sponsor Center